What's Happening?
Scientists, including researchers from Auburn University's Department of Physics, have identified a bacterium from the human urinary tract capable of converting the steroid precursor DHEA into testosterone under laboratory conditions. This discovery,
published in Nature Communications, reveals a previously unknown microbial route to a hormone central to prostate biology. While the finding does not suggest the bacterium causes prostate cancer or that bacterially produced testosterone reaches tumors, it opens new avenues for understanding how microorganisms near the prostate might influence its chemical environment. The research team utilized a rapid screening method called the Human Sterolbiome Discovery High-throughput assay (HSDH assay) to identify Actinobaculum massiliense as the bacterium responsible. Further genomic analysis pinpointed two genes, dirA and dirB, responsible for this conversion. Computational structural biology from Auburn University helped explain the atomic-level mechanisms of these enzymes, showing how DirA's flexible structure allows for versatile steroid transformations, unlike DirB's more restricted capabilities.
Why It's Important?
This discovery is significant because many prostate cancers are androgen-dependent, relying on hormones like testosterone for growth. Current treatments for advanced prostate cancer often focus on reducing testosterone production or blocking its effects. The identification of a urinary bacterium with the molecular machinery to produce testosterone introduces a new variable into the complex understanding of androgen signaling and prostate health. It prompts critical questions about whether microbial metabolism could contribute to the androgen environment near the prostate within the human body. If active, this pathway could influence prostate conditions, disease progression, or even responses to treatment. Furthermore, the study's implications extend beyond prostate research, potentially affecting how urinary steroid profiles are interpreted in medical diagnostics and performance-enhancing drug testing, as microbial transformations could alter these compounds.
What's Next?
The immediate next step for researchers is to determine the physiological relevance of this bacterial testosterone production. This involves investigating whether the pathway is active within the human body, quantifying the amount of androgen bacteria could produce, assessing if these molecules reach nearby prostate tissue, and evaluating any measurable effects on prostate biology. Scientists will also search urinary microbiome datasets for the newly identified genes, dirA and dirB, to understand their prevalence and correlation with urinary hormones, prostate conditions, or treatment outcomes. Future research will aim to bridge the gap between molecular capability observed in the lab and its meaningful impact in the complex environment of the human body, potentially leading to new diagnostic markers or therapeutic targets related to the urinary microbiome.
Beyond the Headlines
This research challenges the traditional view of the urinary tract as sterile and highlights the growing understanding of the urinary microbiome's active role in human physiology. The discovery underscores the intricate interplay between the body's microbial inhabitants and its hormonal systems, suggesting that the influence of the microbiome may be far more pervasive than previously understood. Ethically, this opens discussions about potential interventions targeting the microbiome to modulate hormone levels, which could have broad implications for various hormone-sensitive conditions. Legally, if microbial metabolism significantly alters urinary steroid profiles, it could necessitate re-evaluation of current testing protocols in sports and medicine. Culturally, it reinforces the paradigm shift towards viewing the human body as a complex ecosystem, where microbial communities are active participants in health and disease, pushing the boundaries of how we define and treat physiological imbalances.
